• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Coloproctology >Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients
【24h】

Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients

机译：前期化疗后的短期结果，然后进行转移性结肠癌治疗手术：与前期手术患者的比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Upfront systemic chemotherapy with target agents has been recommended for patients with stage IV colon cancer.Some with partial response are considered for curative resection. There is high risk of developing postoperative complicationsfollowing upfront systemic chemotherapy. We aimed to evaluate short-term perioperative outcomes of curativesurgery after upfront chemotherapy in comparison with upfront surgery in patients with metastatic colon cancer.Methods: Between January 2010 and October 2015, 146 patients (80 in the surgery first group, 66 in the upfront chemotherapygroup) who underwent surgical resection before or after systemic chemotherapy for metastatic colon cancer wereincluded in the present study. All decisions for treatment were made through a multidisciplinary team. Postoperative clinicaloutcomes and complications were analyzed to compare the groups.Results: There was no difference between the 2 groups in terms of postoperative clinical outcomes. Overall complicationrates were not different between the groups (surgery first group: 46.3% vs. upfront chemotherapy group: 60.6%; P =0.084). When classified according to the Clavien-Dindo method, there was no difference between the 2 groups in terms ofmajor complications (grade 3 or more) (surgery first group: 18.9% vs. upfront chemotherapy group: 27.5%; P = 0.374).Conclusion: There was no significant increase in major postoperative complications in metastatic colon cancer patientswho received upfront chemotherapy followed by curative surgery. Careful patient selection and treatment planning areimportant.
机译：目的：推荐用于阶段IV结肠癌患者的前期全身化疗。患有部分反应的患者被认为是治疗切除的。在初期的全身化疗上开发术后并发症的风险很高。我们的旨在评估前期化疗后预期化疗后的愈合术后术后的短期围手术术后，与转移性结肠癌患者的前期手术。方法：2010年1月至2015年10月，146名患者（在手术中的第一个组80例，在预期化学疗法中66名。在本研究中含有半术后的全身化疗之前或之后，在全身化疗之前或之后接受手术切除。所有待遇的决定都是通过多学科团队进行的。分析了术后临床途径和并发症，以比较群体。结果：2组在术后临床结果方面没有差异。总体并发症在群体之间没有差异（手术第一组：46.3％与前期化疗组：60.6％; P = 0.084）。根据Clavien-DINDO方法进行分类，在MAJOR并发症方面的2组之间没有差异（3级或更多）（手术第一组：18.​​9％对前期化疗组：27.5％; P = 0.374）。结论：转移性结肠癌患者的主要术后并发症没有显着增加，其接受疗法疗法疗效。仔细的患者选择和治疗规划呈Imimportant。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号